5-Amino-1MQ

What is 5-Amino-1MQ?#

Evidence Level: Preclinical Only -- All data on 5-Amino-1MQ comes from cell culture and animal studies. No human clinical trials have been published. The information below describes research findings that have not been validated in humans.

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in NAD+ metabolism and cellular energy balance. Unlike traditional peptides, 5-Amino-1MQ is technically a small organic molecule (a methylquinolinium derivative) rather than an amino acid chain, though it is commonly discussed alongside peptides in the biohacking and anti-aging research communities.

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA). This reaction effectively diverts nicotinamide away from the NAD+ salvage pathway, reducing the cell's capacity to regenerate NAD+. By inhibiting this enzyme, 5-Amino-1MQ preserves nicotinamide for NAD+ synthesis, increasing intracellular NAD+ levels through a mechanism entirely distinct from NAD+ precursor supplementation (NMN, NR).

The compound has attracted significant interest in preclinical research for its effects on adipocyte metabolism, body composition, and muscle function in animal models. However, it is critical to note that no human clinical trials have been published, and the safety and efficacy of 5-Amino-1MQ in humans remain unknown.

Mechanism of Action#

Preclinical mechanism -- The following description is based on cell culture and animal studies. Human relevance has not been confirmed.

5-Amino-1MQ's mechanism centers on NNMT inhibition:

• NNMT inhibition: Selectively blocks NNMT with an IC50 of approximately 1.2 microM. Does not significantly inhibit related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway
• NAD+ increase: By preventing nicotinamide methylation to 1-MNA, more nicotinamide remains available for conversion to NMN and subsequently to NAD+ via the salvage pathway. In adipocytes, this produces a 1.2 to 1.6-fold increase in intracellular NAD+
• Lipogenesis suppression: Increased NAD+ availability in adipocytes suppresses lipogenic pathways, reducing fat synthesis and storage
• SAM/SAH ratio modulation: Inhibiting NNMT's consumption of SAM alters the SAM/S-adenosylhomocysteine (SAH) ratio, which may affect broader methylation dynamics
• Muscle effects: In aged mice, NNMT inhibition improved muscle proteome and metabolome profiles through mechanisms distinct from exercise, suggesting direct effects on muscle cell biology

How 5-Amino-1MQ Differs from NAD+ Precursors#

These approaches are mechanistically complementary, though their combination has not been studied.

Research Overview#

No human data -- All studies described below are preclinical (cell culture or animal models).

5-Amino-1MQ has been evaluated in three key preclinical studies:

• Obesity model (2018): Subcutaneous injection in diet-induced obese mice for 11 days significantly reduced body weight, white adipose mass, and adipocyte size without affecting food intake (PMID: 29155147)
• Microbiome study (2022): Combined with caloric restriction in obese mice, 5-Amino-1MQ normalized body composition and established a distinct gut microbiome signature, including increased Lactobacillus abundance (PMID: 35013352)
• Muscle function (2024): In aged mice, NNMT inhibition produced 40% greater grip strength than sedentary controls, and combined with exercise achieved 60% improvement. Effects were additive with exercise, suggesting distinct molecular mechanisms (PMID: 38969654)

Important Considerations#

Critical warning: 5-Amino-1MQ is a preclinical research compound. No human clinical trials have been published. The following points are essential to understand before interpreting the research data.

• No human safety data: The complete absence of human clinical trials means the safety profile, side effects, optimal dosing, and pharmacokinetics in humans are entirely unknown
• Animal-to-human translation is uncertain: Metabolic differences between mice and humans mean that the magnitude of effects (e.g., weight loss, grip strength improvement) may not translate. Many compounds that show promise in mice fail in human trials
• Not FDA-approved: 5-Amino-1MQ is not approved by any regulatory agency for any indication. It is sold as a research chemical
• NNMT inhibition has broad implications: NNMT is involved in multiple metabolic pathways beyond NAD+, including methylation balance, polyamine metabolism, and one-carbon metabolism. Long-term consequences of NNMT inhibition are unknown
• Dosing is not established: No human dosing protocol has been validated. Animal doses cannot be directly extrapolated to humans

Key Research Findings#

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice, published in Biochemical Pharmacology (Neelakantan H et al., 2018; PMID: 29155147):

• 5-Amino-1MQ showed NNMT selectivity with IC50 of 1.2 microM
• Reduced body weight and white adipose mass in diet-induced obese mice over 11 days
• No effect on food intake, suggesting metabolic rather than appetitive mechanism

Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice, published in Scientific Reports (Dimet-Wiley AL et al., 2024; PMID: 38969654):

• NNMT inhibition alone improved grip strength by 40% in aged sedentary mice
• Combined with exercise, grip strength improved by 60% over sedentary controls
• Proteomic and metabolomic analyses revealed distinct molecular mechanisms from exercise

Related Reading#

• 5-Amino-1MQ research studies and evidence
• 5-Amino-1MQ dosing information
• 5-Amino-1MQ side effects profile
• NAD+ research guide
• MOTS-c research guide